S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?

United Therapeutics (UTHR) Stock Price, News & Analysis

$229.72
-13.55 (-5.57%)
(As of 03/28/2024 ET)
Today's Range
$229.14
$243.57
50-Day Range
$210.76
$249.51
52-Week Range
$204.44
$261.54
Volume
1.11 million shs
Average Volume
420,931 shs
Market Capitalization
$10.81 billion
P/E Ratio
11.58
Dividend Yield
N/A
Price Target
$294.40

United Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
28.2% Upside
$294.40 Price Target
Short Interest
Bearish
4.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
0.86mentions of United Therapeutics in the last 14 days
Based on 29 Articles This Week
Insider Trading
Selling Shares
$17.89 M Sold Last Quarter
Proj. Earnings Growth
4.07%
From $23.32 to $24.27 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.96 out of 5 stars

Medical Sector

50th out of 938 stocks

Pharmaceutical Preparations Industry

22nd out of 425 stocks

UTHR stock logo

About United Therapeutics Stock (NASDAQ:UTHR)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Stock Price History

UTHR Stock News Headlines

Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
United Therapeutics (NASDAQ:UTHR) Shares Gap Up to $237.90
A lot of people are making this costly mistake
You may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time.
StockNews.com Lowers United Therapeutics (NASDAQ:UTHR) to Buy
United Therapeutics To Repurchase Up To $1 Bln Shares
UTHR Aug 2024 170.000 put
UTHR Apr 2024 210.000 put
Q4 2023 Liquidia Corp Earnings Call
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
1,168
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$294.40
High Stock Price Target
$330.00
Low Stock Price Target
$215.00
Potential Upside/Downside
+28.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$984.80 million
Pretax Margin
54.75%

Debt

Sales & Book Value

Annual Sales
$2.33 billion
Cash Flow
$20.47 per share
Book Value
$127.35 per share

Miscellaneous

Free Float
41,177,000
Market Cap
$10.81 billion
Optionable
Optionable
Beta
0.52

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives


UTHR Stock Analysis - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price target for 2024?

11 equities research analysts have issued 1 year price targets for United Therapeutics' shares. Their UTHR share price targets range from $215.00 to $330.00. On average, they anticipate the company's stock price to reach $294.40 in the next year. This suggests a possible upside of 28.2% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2024?

United Therapeutics' stock was trading at $219.89 on January 1st, 2024. Since then, UTHR shares have increased by 4.5% and is now trading at $229.72.
View the best growth stocks for 2024 here
.

Are investors shorting United Therapeutics?

United Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 1,920,000 shares, an increase of 64.1% from the February 29th total of 1,170,000 shares. Based on an average daily trading volume, of 406,600 shares, the days-to-cover ratio is currently 4.7 days. Approximately 4.4% of the shares of the company are sold short.
View United Therapeutics' Short Interest
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, February, 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.28 by $0.08. The biotechnology company earned $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a trailing twelve-month return on equity of 17.72% and a net margin of 42.31%. The company's revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.67 EPS.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.95%), Vanguard Group Inc. (9.93%), Wellington Management Group LLP (8.06%), Avoro Capital Advisors LLC (6.08%), Dimensional Fund Advisors LP (1.20%) and Nuveen Asset Management LLC (1.05%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:UTHR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners